SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will webcast
its Quarterly Update Conference Call for the fourth quarter 2018 on
Thursday, February 21 at 4:30 p.m. ET / 1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date, Halozyme will release financial results for the fourth
quarter and year ended December 31,
2018 following the close of trading.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately fifteen
minutes prior to the call to register, download and install any
necessary audio software. The live call may be accessed by dialing
(877) 410-5657 (domestic callers) or (334) 323-7224 (international
callers) using passcode 387156. A telephone replay will be
available after the call by dialing (877) 919-4059 (domestic
callers) or (334) 323-0140 (international callers) using replay ID
number 68892505.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a
unique approach to targeting solid tumors, allowing increased
access of co-administered cancer drug therapies to the tumor in
animal models. PEGPH20 is currently in development for the
treatment of several cancers and has the potential to be used in
combination with different types of cancer therapies. In addition
to its proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical and
biotechnology companies, including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its
ENHANZE® drug delivery technology. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-host-fourth-quarter-and-full-year-2018-financial-results-webcast-and-conference-call-300792018.html
SOURCE Halozyme Therapeutics, Inc.